Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2022

16.03.2021 | Original Article

Inappropriateness of Proton Pump Inhibitors After Hospital Discharge Is Associated with Thirty-Day Hospital Readmission

verfasst von: John W. Blackett, Ling Chen, Jianhua Li, Jason D. Wright, Daniel E. Freedberg

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background and Aims

Concerns have been raised about the adverse effects of proton pump inhibitors (PPIs). Rather than PPIs themselves causing harm, we hypothesized that PPIs prescribed without appropriate indications would be associated with adverse outcomes compared to appropriately indicated PPIs.

Methods

Adult patients initiated on a new PPI during a hospitalization at our institution from 2014 to 2018 were analyzed. The primary outcome was all-cause 30-day readmission rate. The primary exposure was long-term appropriateness of PPI determined by the presence of prespecified diagnostic codes and discharge medications. Logistic regression modeling was used to estimate the odds of 30-day readmission in patients discharged on inappropriate compared to appropriate new PPIs.

Results

Of 84,236 patients admitted to our institution, 7745 (9.2%) were discharged on a new PPI, of which 5136 (66.3%) lacked an appropriately documented indication. Inappropriate PPIs were associated with 30-day hospital readmission after adjusting for other factors (adjusted odds ratio 1.30, 95% confidence interval 1.10–1.53). The excess risk associated with lack of appropriate documentation for PPIs in these patients was 44 readmissions per 1000 hospitalizations (95% confidence interval 21–67).

Conclusions

Discharge on inappropriate PPIs was associated with 30-day hospital readmission compared to appropriate PPIs. The harm associated with inappropriate PPIs is not likely due to direct effects of PPIs because all patients in the study received PPIs. Rather, patients who receive inappropriate PPIs may have additional patient-specific factors that place them at increased risk for hospital readmission.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Betteridge TM, Frampton CM, Jardine DL. Polypharmacy—we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J. 2012;42:208–211CrossRef Betteridge TM, Frampton CM, Jardine DL. Polypharmacy—we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J. 2012;42:208–211CrossRef
2.
Zurück zum Zitat Hubbard RE, Peel NM, Scott IA et al. Polypharmacy among inpatients aged 70 years or older in Australia. Med J Aust. 2015;202:373–377CrossRef Hubbard RE, Peel NM, Scott IA et al. Polypharmacy among inpatients aged 70 years or older in Australia. Med J Aust. 2015;202:373–377CrossRef
3.
Zurück zum Zitat Qato DM, Alexander GC, Conti RM et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–2878CrossRef Qato DM, Alexander GC, Conti RM et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–2878CrossRef
4.
Zurück zum Zitat Kantor ED, Rehm CD, Haas JS et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314:1818–1831CrossRef Kantor ED, Rehm CD, Haas JS et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314:1818–1831CrossRef
5.
Zurück zum Zitat Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286–296CrossRef Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286–296CrossRef
6.
Zurück zum Zitat Dean BB, Gano AD Jr, Knight K et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664CrossRef Dean BB, Gano AD Jr, Knight K et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664CrossRef
7.
Zurück zum Zitat Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16:e228–e234.PubMed Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16:e228–e234.PubMed
8.
Zurück zum Zitat Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104:S27-32PubMed Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104:S27-32PubMed
9.
Zurück zum Zitat Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48CrossRef Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48CrossRef
10.
Zurück zum Zitat Lambert AA, Lam JO, Paik JJ et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015;10:e0128004CrossRef Lambert AA, Lam JO, Paik JJ et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015;10:e0128004CrossRef
11.
Zurück zum Zitat Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–246CrossRef Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–246CrossRef
12.
Zurück zum Zitat Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27:3153–3163CrossRef Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27:3153–3163CrossRef
13.
Zurück zum Zitat Shah NH, LePendu P, Bauer-Mehren A et al. Proton Pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653CrossRef Shah NH, LePendu P, Bauer-Mehren A et al. Proton Pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653CrossRef
14.
Zurück zum Zitat Maggio M, Lauretani F, Ceda GP et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437–442CrossRef Maggio M, Lauretani F, Ceda GP et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437–442CrossRef
15.
Zurück zum Zitat Haenisch B, von Holt K, Wiese B et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–428CrossRef Haenisch B, von Holt K, Wiese B et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–428CrossRef
16.
Zurück zum Zitat Willems RPJ, van Dijk K, Ket JCF, et al. Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis. JAMA Intern Med. 2020. Willems RPJ, van Dijk K, Ket JCF, et al. Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis. JAMA Intern Med. 2020.
17.
Zurück zum Zitat Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–715CrossRef Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–715CrossRef
18.
Zurück zum Zitat Moayyedi P, Eikelboom JW, Bosch J et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–691.CrossRef Moayyedi P, Eikelboom JW, Bosch J et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–691.CrossRef
19.
Zurück zum Zitat Wimmer BC, Cross AJ, Jokanovic N et al. Clinical outcomes associated with medication regimen complexity in older people: a systematic review. J Am Geriatr Soc. 2017;65:747–753CrossRef Wimmer BC, Cross AJ, Jokanovic N et al. Clinical outcomes associated with medication regimen complexity in older people: a systematic review. J Am Geriatr Soc. 2017;65:747–753CrossRef
20.
Zurück zum Zitat Marcum ZA, Amuan ME, Hanlon JT et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60:34–41CrossRef Marcum ZA, Amuan ME, Hanlon JT et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60:34–41CrossRef
21.
Zurück zum Zitat Kojima T, Akishita M, Nakamura T et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12:425–430CrossRef Kojima T, Akishita M, Nakamura T et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12:425–430CrossRef
22.
Zurück zum Zitat Ziere G, Dieleman JP, Hofman A et al. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61:218–223CrossRef Ziere G, Dieleman JP, Hofman A et al. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61:218–223CrossRef
23.
Zurück zum Zitat Hein C, Forgues A, Piau A et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15:850 e11–5CrossRef Hein C, Forgues A, Piau A et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15:850 e11–5CrossRef
24.
Zurück zum Zitat Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275:852–857CrossRef Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275:852–857CrossRef
25.
Zurück zum Zitat Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure—a register-based study in Sweden 2005–2009. Health Policy. 2013;109:166–174CrossRef Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure—a register-based study in Sweden 2005–2009. Health Policy. 2013;109:166–174CrossRef
26.
Zurück zum Zitat Akazawa M, Imai H, Igarashi A et al. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8:146–160CrossRef Akazawa M, Imai H, Igarashi A et al. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8:146–160CrossRef
27.
Zurück zum Zitat Lin HW, Lin CH, Chang CK et al. Economic outcomes of pharmacist-physician medication therapy management for polypharmacy elderly: a prospective, randomized, controlled trial. J Formos Med Assoc. 2018;117:235–243CrossRef Lin HW, Lin CH, Chang CK et al. Economic outcomes of pharmacist-physician medication therapy management for polypharmacy elderly: a prospective, randomized, controlled trial. J Formos Med Assoc. 2018;117:235–243CrossRef
28.
Zurück zum Zitat Kojima G, Bell C, Tamura B et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc. 2012;13:818 e11–5CrossRef Kojima G, Bell C, Tamura B et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc. 2012;13:818 e11–5CrossRef
29.
Zurück zum Zitat Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27–37CrossRef Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27–37CrossRef
31.
Zurück zum Zitat Leri F, Ayzenberg M, Voyce SJ et al. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106:270–273CrossRef Leri F, Ayzenberg M, Voyce SJ et al. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106:270–273CrossRef
32.
Zurück zum Zitat Reid M, Keniston A, Heller JC et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7:421–425CrossRef Reid M, Keniston A, Heller JC et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7:421–425CrossRef
33.
Zurück zum Zitat Lee TC, McDonald EG. Deprescribing proton pump inhibitors: overcoming resistance. JAMA Intern Med. 2020;180:571–573.CrossRef Lee TC, McDonald EG. Deprescribing proton pump inhibitors: overcoming resistance. JAMA Intern Med. 2020;180:571–573.CrossRef
34.
Zurück zum Zitat Bustillos H, Leer K, Kitten A et al. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. PLoS One. 2018;13:e0208461CrossRef Bustillos H, Leer K, Kitten A et al. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. PLoS One. 2018;13:e0208461CrossRef
35.
Zurück zum Zitat Ladd AM, Panagopoulos G, Cohen J et al. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347:446–451CrossRef Ladd AM, Panagopoulos G, Cohen J et al. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347:446–451CrossRef
Metadaten
Titel
Inappropriateness of Proton Pump Inhibitors After Hospital Discharge Is Associated with Thirty-Day Hospital Readmission
verfasst von
John W. Blackett
Ling Chen
Jianhua Li
Jason D. Wright
Daniel E. Freedberg
Publikationsdatum
16.03.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06909-3

Weitere Artikel der Ausgabe 3/2022

Digestive Diseases and Sciences 3/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Intoxikation ohne Alkoholaufnahme: An das Eigenbrauer-Syndrom denken!

05.06.2024 Internistische Diagnostik Nachrichten

Betrunken trotz Alkoholabstinenz? Der Fall einer 50-jährigen Patientin zeigt, dass dies möglich ist. Denn die Frau litt unter dem Eigenbrauer-Syndrom, bei dem durch Darmpilze eine alkoholische Gärung in Gang gesetzt wird.

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.